ARYL HYDROCARBON RECEPTOR BLOCKS AGING-INDUCED SENESCENCE IN THE LIVER AND FIBROBLAST CELLS

Ana Nacarino-Palma\textsuperscript{1,2}, Eva M. Rico-Leo\textsuperscript{1,2}, Judith Campisi\textsuperscript{3,4}, Arvind Ramanathan\textsuperscript{3}, Jaime M. Merino\textsuperscript{1,2,*} and Pedro M. Fernández-Salguero\textsuperscript{1,2,*}

\textsuperscript{1}Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias, Universidad de Extremadura, Avenida de Elvas s/n, 06071 Badajoz, Spain; \textsuperscript{2}Instituto Universitario de Investigación Biosanitaria de Extremadura (INUBE), Avenida de la Investigación s/n, 06071 Badajoz, Spain; \textsuperscript{3}Buck Institute for Research on Aging, 8001 Redwood Boulevard, Novato, CA 94945, USA; \textsuperscript{4}Lawrence Berkeley National Laboratory, 1 Cyclotron Rd., Berkeley, CA 94720, USA.

*Corresponding authors:

Pedro M. Fernández-Salguero, Email: pmfersal@unex.es
Jaime M. Merino, Email: jmerino@unex.es

Tel: +34 924289300 Ext. 86895

**Keywords:** Aryl hydrocarbon receptor, Hepatocarcinogenesis, Senescence, Metabolism

**Abbreviations:** AhR, Aryl Hydrocarbon Receptor; C12FDG, 5-Dodecanoylaminofluorescein Di-β-D-Galactopyranoside; FICZ, 6-formyl-indolo (3,2-b) carbazole; HGF, Hepatocyte growth factor; SASP, Senescence-associated secretory phenotype; TMRM, Tetramethylrhodamine; TTF, Tail tip fibroblast; VEGF, Vascular-endothelial growth factor
ABSTRACT

Aging induces progressive organ degeneration and worsening of tissue homeostasis leading to multiple pathologies. Yet, little is known about the mechanisms and molecular intermediates involved. Here, we report that aged aryl hydrocarbon receptor-null mice (AhR-/−) had exacerbated senescence and larger numbers of liver progenitor cells. Senescence-associated markers β-galactosidase (SA-β-Gal), p16\(^{ink4a}\) and p21\(^{Cip1}\) and genes of the senescence-associated secretory phenotype (SASP) TNF and IL1 were overexpressed in aged AhR-/− livers. AhR binding to the promoter of those genes, as shown by chromatin immunoprecipitation, likely had a repressive effect maintaining their physiological levels in AhR+/+ livers. Furthermore, factors secreted by senescent cells MCP-2, MMP12 and FGF were also produced at higher levels in aged AhR-null livers. Supporting the linkage between senescence and stemness, liver progenitor cells were more abundant in AhR-/− mice, which could probably contribute to their increased hepatocarcinoma burden. These roles of AhR are not liver-specific since adult and embryonic AhR-null fibroblasts acquired cellular senescence upon culturing with overexpression of SA-β-Gal, p16\(^{ink4a}\) and p21\(^{Cip1}\). Notably, depletion of senescent cells with the senolytic agent navitoclax restored basal expression of senescent markers in AhR-/− fibroblasts. Oppositely, senescence promoter palbociclib induced an AhR-null like phenotype in AhR+/+ fibroblasts. Moreover, doxycycline-induced senescence reduced AhR levels while depletion of p16\(^{ink4a}\)-expressing senescent cells restored basal AhR levels in mouse lungs. Thus, AhR is needed to restrict age-induced senescence, and such activity seems to correlate with a more differentiated phenotype and with increased resistance to liver tumorigenesis.
INTRODUCTION

The aryl hydrocarbon receptor (AhR) is a transcription factor with important roles in toxicology and cell physiology (Fan et al., 2010; Puga et al., 2005; Roman et al., 2018). AhR has a significant role in essential signaling pathways controlling cell cycle control, cell-cell contact, apoptosis, angiogenesis, differentiation and pluripotency (Cho et al., 2004; Ito et al., 2004; Morales-Hernandez et al., 2016; Roman et al., 2009). Deregulation of these pathways, critical for the maintenance of cellular homeostasis, predispose organisms to develop different pathologies including cancer (Fan et al., 2010; Mulero-Navarro and Fernandez-Salguero, 2016; Safe et al., 2013).

Recent findings have uncovered important roles of AhR in cell differentiation and pluripotency, eventually supporting its impact as therapeutic target (Ko and Puga, 2017; Morales-Hernandez et al., 2016; Mulero-Navarro and Fernandez-Salguero, 2016). Previous work from our group demonstrate that AhR adjusts liver and lung regeneration upon injury by controlling proliferation and the expansion of pluripotent stem-like cells (Morales-Hernandez et al., 2017; Moreno-Marín et al., 2017). Accordingly, lack of AhR (AhR/-) induces an undifferentiated and non-polyploid phenotype in the mouse liver that persists from preweaning to adulthood (Moreno-Marín et al., 2018). Moreover, increased numbers of stem cells in AhR/- mouse livers correlates with their higher susceptibility to develop diethylnitrosamine (DEN)-induced hepatocarcinomas (Fan et al., 2010; Moreno-Marín et al., 2017).

In addition to multiple genetic and environmental causes, aging remains a major risk factor in developing cancer (Kruk et al., 2019). During the aging process, biological systems undergo progressive degeneration with the accumulation of molecular changes that compromise and decrease physiological and fertility functions, ultimately leading to loss of homeostasis and elderly pathologies. In addition, impaired cellular and molecular
functions during aging may trigger new and aberrant regenerative capacities leading to the appearance of hyperplasic pathologies (Campisi and Robert, 2014).

Most age-related pathologies, degenerative or hyperplastic, are linked to a stress response called senescence. Senescence consists of an irreversible arrest of the cell cycle, changes in chromatin organization and alteration of gene expression patterns (Gorgoulis et al., 2019; Hernandez-Segura et al., 2018). Such phenotype includes secretion of pro-inflammatory cytokines, chemokines, growth factors and proteases, generating a senescence-associated secretory phenotype (SASP) (Campisi and di Fagagna, 2007). The former cellular response to senescence is to halt proliferation of damaged cells, thus evolving as a protective and barrier mechanism against the development of cancer (Campisi and Robert, 2014; Coppe et al., 2008; Rhinn et al., 2019). Moreover, the fact that SASP has multiple paracrine activities suggests that senescence not only prevents cancer but also serves to promote tissue repair and regeneration upon injury (Campisi, 2013; Chiche et al., 2020; Rhinn et al., 2019). In addition, SASP factors can enhance tumorigenesis by promoting proliferation, metastasis and immunosuppression (Wang et al., 2020). A relevant link has been identified between senescence and cellular reprogramming since in vivo reprogramming can induce tumor- (Abad et al., 2013; Mosteiro et al., 2016) and aging-associated senescence (Chiche et al., 2020) by mechanisms probably requiring an exacerbated inflammatory status.

An early report revealed that mouse embryo fibroblasts (MEFs) from AhR-/- mice reached senescence earlier than AhR+/+ cells during adipogenic differentiation (Alexander et al., 1998). Later work has shown that AhR reduces smoking-induced inflammation in the lung parenchyma through, among other mechanisms, the control of senescence (Guerrina et al., 2018). In addition, air-born environmental particles can
promote cellular senescence through AhR by the production of reactive oxygen species (ROS) causing epigenetic modifications leading to p16\textsuperscript{Ink4a} activation (Ryu et al., 2019).

Here, we report that aged mice lacking AhR expression have a significant increase in hepatic senescence that correlates with an enhanced content of liver progenitor cells and with a larger incidence in hepatocarcinoma burden. Such phenotype involves altered expression of typical senescence and SASP-related markers. AhR deficiency also induced senescence in adult and embryonic fibroblasts, in which its incidence could be modulated by senolytic or senescence promoters in a receptor-dependent manner. Given the recently discovered functional link between senescence and reprogramming, it seems plausible that AhR acts to properly control the balance of both processes during physiological aging. Such relationship may also underline the exacerbated regenerative response developed by AhR-null mice in liver and lung upon injury.
RESULTS

AhR depletion increases liver tumor burden with aging.

Adult AhR-null mice maintain an undifferentiated and non-polyploid liver phenotype (Moreno-Marin et al., 2018) that could favor the appearance of age-related hepatocarcinogenesis. To address this issue, we examined AhR+/+ and AhR−/− mice aged 15 to 22 months for the presence of liver tumors. Lack of AhR lead to the generation of liver tumors that were evident at 18 months of age and that accounted for a large fraction of the liver at 22 months (Fig. 1A). AhR−/− tumors were larger in size, more vascularized and presenting pyknotic nuclei at the histological level that were suggestive of chromatin condensation and replicative blockade (Fig. 1B). The overall tumor incidence reached values close to 45% of the AhR-null mice and remained below 20% of the AhR wild type animals (Fig. 1C). Additionally, spontaneous hepatocarcinogenesis affected close to 80% of AhR−/− mice of the C56BL/J genetic background, confirming that AhR depletion favors liver tumor promotion (results not shown). To determine if lower AhR levels are in fact associated to increased liver tumorigenesis, we next analyzed AhR expression during aging. As shown in Fig. 1D, AhR mRNA expression drastically decreased in AhR+/+ livers from 14 months and remained low until at least 22 months of age. Consistently, a similar protein expression profile was found by immunoblotting analysis of liver extracts from both genotypes (Fig. 1E). Treatment with the physiological agonist FICZ significantly increased liver mRNA levels of the canonical target gene Cyp1a1 in AhR+/+ young mice. Further, aging markedly reduced the ability of FICZ to induce Cyp1a1 expression in AhR expressing liver (Fig. 1F), hence supporting that AhR downregulation may have a causal role in liver hepatocarcinogenesis. In agreement with the known role of AhR in controlling pluripotency and stemness (Ko and Puga, 2017; Mulero-Navarro and Fernandez-Salguero, 2016), enhanced hepatocarcinogenesis in AhR-null liver
correlated with their higher numbers of liver progenitor/stem-like cells in both young and aged animals (Fig. 1G). Interestingly, AhR deficiency also produced an increase in bone marrow progenitor cells regardless of the age of mice (Fig. 1H), thus confirming the role of this receptor in maintaining the population of undifferentiated cells in different organs. Enhanced tumor burden in AhR-/ mouse liver correlated with increased expression of the glucose transporter Glut4 not only in old by also in young mice (Supplementary Fig. 1A). Accordingly, glucose uptake, as determined by the level of hexokinase activity, was significantly higher in old AhR-null than in AhR+/+ mice (Supplementary Fig. 1B).

Thus, aging in AhR/- mice induces a preferred glycolytic metabolism that could impact their greater susceptibility to develop liver cancer and that correlates with the Warburg effect.

AhR deficient livers have increased senescence with aging

An undifferentiated status favors hepatocarcinogenesis (Kuo et al., 2016; Yin et al., 2015) whereas senescence seems to have an important role in the fate of aged undifferentiated tumors (Chiche et al., 2020; Mosteiro et al., 2018). We then investigated whether AhR deficiency in aged liver could induce a senescent status eventually linked to the generation of hepatic tumors. Senescence-associated β-galactosidase activity (SA-β-Gal) was markedly increased in liver sections from aged AhR/- mice as compared to their AhR+/+ counterparts (Fig. 2A). Quantification of senescence in C12FDG-labelled hepatic cells by FACS confirmed that AhR deficiency significantly expanded the number of senescent cells upon aging (Fig. 2B). Next, we used liver mRNA to analyze by RT-qPCR the expression of genes considered drivers of senescence. The results showed that, with respect to AhR+/+ livers, p16Ink4a mRNA levels markedly increased in AhR/- livers at 15 months to decrease to lower levels at 22 months of age (Fig. 2C). Similarly, p21Cip1 transiently increased in AhR/- livers at 15 months reaching values significantly higher to
those of AhR+/+ livers; differences in p21Cip1 expression between both genotypes could be seen even in young mice (Fig. 2D). The expression of markers involved in the senescence-associated secretory phenotype (SASP) IL1 and TNFα was also up-regulated with aging in absence of AhR (Fig. 2E,F), although TNFα remained at higher levels even at the oldest age analyzed (22 months). We did not detect significant transcriptional changes between both genotypes with respect to liver p53 or IL6 (data not shown). Thus, AhR limits senescence and carcinogenesis in the liver and such activities could be related to its potential to maintain differentiation in this organ.

To further correlate undifferentiation and senescence in the liver, we analyzed markers of both processes in non-tumoral tissue from old mice and in hepatocarcinoma samples from AhR+/+ and AhR-/− mice by immunofluorescence. Regarding senescence, p16Ink4a and p21Cip1 were present at higher levels in the liver of aged AhR-null mice as compared to wild mice. Pluripotency/stemness and undifferentiation inducers NANOG and OCT4 were also overexpressed in AhR-/− livers of old mice (Fig. 3). Expression of p21Cip1 and OCT4 appeared to be prevalent with respect to p16Ink4a and NANOG, respectively. Well-developed hepatocarcinomas from AhR-/− mice (Fig. 1) showed even higher levels of each of those proteins, suggesting that tumorigenesis accentuate the basal undifferentiated and senescent status of aged AhR-/− mice. The mesenchymal marker α-smooth muscle actin (α-SMA) had increased levels in hepatocarcinomas and old AhR-/− liver as compared to livers of AhR+/+ mice (Fig. 3), in agreement with the known accumulation of extracellular matrix in old AhR-null liver (Fernandez-Salguero et al., 1995; Schmidt et al., 1996) that may eventually contribute to hepatocarcinogenesis.

Since senescence markers were up-regulated at the mRNA level in absence of AhR (Fig. 2), we next decided to analyze if AhR transcriptionally represses those genes by direct binding to their promoters. Sequence analysis revealed the presence of the AhR-
canonical binding site XRE (Xenobiotic response element, 5′-GCATG 3′) in the upstream promoter region of p16\textsuperscript{Ink4a}, p21\textsuperscript{Cip1} and TNFα. Chromatin immunoprecipitation (ChIP) for AhR in liver extracts from young mice (2 months) and mice aged 15 and 22 months was performed (Fig. 4). AhR was bound to the p16\textsuperscript{Ink4a} gene promoter at 15 months to be released in older animals at 22 months (Fig. 4A). AhR binding to the p21\textsuperscript{Cip1} and TNFα gene promoters was maximal at 22 months of age and nearly basal in younger mice (Fig. 4B,C). Thus, overexpression of these genes in old AhR\textsuperscript{-/-} livers likely results from a lack of transcriptional repression in absence of receptor.

Factors of the senescence-associated secretory phenotype are regulated in an AhR-dependent manner during liver aging.

Soluble factors secreted by senescent cells could contribute to the aging phenotype of AhR\textsuperscript{-/-} mouse liver. To address that, we used immunoassays to analyze the levels of major SASP factors secreted within the liver or circulating in the blood of AhR\textsuperscript{+/+} and AhR\textsuperscript{-/-} aged mice. In the liver, secretion of MCP2/CCL8, a cytokine responsible for chemoattraction of monocytes and macrophages to damaged or tumor areas, was significantly higher in AhR\textsuperscript{-/-} mice at 22 months as compared to age-matched AhR\textsuperscript{+/+} mice (Fig. 4D). Extracellular matrix metalloproteinase MMP-12, a stimulator of matrix degradation and liver tumor progression, was significantly overexpressed not only in the oldest (e.g., 22 months) but also in mice at the beginning of the aging process (e.g., 15 months) (Fig. 4E). Moreover, fibroblast growth factor (FGF), whose expression seems to inhibit senescence (Coutu and Galipeau, 2011), had a trend to decrease in AhR\textsuperscript{-/-} liver with aging, despite having higher levels than wild type mice at 15 months (Fig. 4F). Liver hepatocyte growth factor (HGF), whose overactivation has been related to senescence inhibition (Zhu et al., 2014), was also reduced at 15 months and not significantly increased in older 22 months AhR-null mice (Fig. 4G). In serum, HGF levels were
significantly lower in oldest 22 months $AhR^{-/-}$ mice (Fig. 4H), as it was the amount of circulating vascular endothelial growth factor (VEGF) (Fig. 4I), in agreement with its implication in aging-related endothelial senescence (Regina et al., 2016). Thus, the SASP appears to be exacerbated in $AhR^{-/-}$ liver during aging.

**Cell senescence markers are enhanced in adult primary fibroblasts lacking AhR**

To investigate if the role of AhR in senescence is extensive to additional cell types, we decided to examine adult primary fibroblasts as they are known targets of senescence (Alvarez et al., 2017; Zorin et al., 2017) and can be readily isolated from adult $AhR^{+/+}$ and $AhR^{-/-}$ tissues. Adult tail tip fibroblasts (TTFs) from young (4-6 weeks) and old mice (15-22 months) of both genotypes were isolated, cultured and analyzed for their senescence level using the SA-β-Gal fluorescent substrate C12FDG (Fig. 5). Fluorescent confocal microscopy revealed that both young and old $AhR^{-/-}$ TTFs had larger numbers of senescent cells than $AhR^{+/+}$ TTFs grown under the same culturing conditions (Fig. 5A). Flow cytometry similarly showed that lack of AhR significantly increased the population of senescent cells in $AhR^{-/-}$ TTFs at both ages, as revealed by C12FDG fluorescence (Fig. 5B). Cells positive for $p16^{Ink4a}$ were equally abundant in young TTFs of both genotypes but markedly increased in old $AhR^{-/-}$ cells (Fig. 5C). Regarding $p21^{Cip1}$ a similar response was found in $AhR^{-/-}$ TTFs with aging, being its expression nuclear in a large fraction of cells (Fig. 5D). On the other hand, old $AhR^{-/-}$ TTFs had a larger number of Cyclin E positive cells than old $AhR^{+/+}$ TTFs (Fig. 5E), together with a higher percentage of cells at the G0/G1 transition of the cell cycle that was also present in young AhR-null cells (Fig. 5F). These results suggest that a concurrent increase in Cyclin E and tumor suppressors may cause cell cycle blockade, reduced proliferation of adult $AhR^{-/-}$ fibroblasts (Mulero-Navarro et al., 2005; Zaher et al., 1998) and eventually contribute to higher rates of senescence.
Mitochondrial dysfunction is an additional parameter indicative of cellular senescence (Moro, 2019). We thus measured the mitochondrial membrane potential (MMP) of young and old AhR+/+ and AhR-/− TTFs. Flow cytometry analyses using tetramethyl rhodamine (TMRM), a fluorescent cationic dye captured by active mitochondria, showed that old AhR-null TTFs had reduced mitochondrial activity than AhR+/+ cells (Fig. 5G). We latter used the JC10 probe, which forms aggregates depending on membrane polarization, to further support that old AhR-/− mice had lower mitochondrial metabolism (Fig. 5H). Therefore, aged primary adult fibroblasts have increased senescence rates, reduced cell cycling and mitochondrial dysfunction suggestive of glycolytic metabolism.

Embryonic primary fibroblasts lacking AhR expression have increased senescence rates

AhR-null mouse embryonic fibroblasts (MEF), on in vitro passaging, acquire a senescent phenotype earlier than wild type cells (Alexander et al., 1998) and have reduced proliferation potential (Santiago-Josefat et al., 2004). Flow cytometry and cytological staining for SA-β-Gal indicated that, upon in vitro culturing, AhR-null MEFs had higher levels of senescence than AhR+/+ MEFs, which became significant from passage 3 (P3) (Fig. 6A-C). AhR expression gradually increased with the number of passages from P2 to P5 (Fig. 6D), a result suggesting that, in undifferentiated AhR+/+ embryonic cells, AhR up-regulation may be a response to restrict senescence and that full receptor depletion may exacerbate such process. Consistently, senescence drivers p16Ink4a and p21Cip1 were up-regulated in AhR-/− MEFs with the number of passages following a pattern closely to that of accumulation of senescent cells (Fig. 6E,F). Levels of p53 did not significantly change during in vitro passaging in either genotype (Fig. 6G).
To further characterize the contribution of AhR to cellular senescence, we choose to treat MEF cells with specific inhibitors and activators of the process. Bcl-2 family inhibitor Navitoclax is a senolytic agent able to block cell senescence (Zhu et al., 2016). Navitoclax significantly reduced senescence rates in AhR+/+ and AhR/-/ MEFs with respect to untreated control cultures (Fig. 7A-C). In agreement with the up-regulation of AhR in wild type senescent cells (Fig. 6D), Navitoclax induced a decrease in receptor levels (Fig. 7D) that again suggest a coordinated regulation between its expression and the magnitude of senescence. As expected, this senolytic compound significantly reduced the expression of senescence markers p16\textsuperscript{Ink4a} and p21\textsuperscript{Cip1} in AhR-/− MEFs as compared with vehicle-treated cultures (Fig. 7E,F). However, Navitoclax appeared to increase p53 levels in AhR deficient MEF cells (Fig. 7G).

CDK4/6 inhibitor Palbociclib/PD0332991 has been identified as a cell cycle inhibitor and senescence inducer (Yoshida et al., 2016). Palbociclib efficiently increased senescence rates in both AhR+/+ and AhR−/− MEFs although its effects were more pronounced in the former due to their lower basal incidence of senescent cells (Fig. 8A-C). Treatment of wild type MEFs at passage 2 with Palbociclib for 8 days did not alter AhR expression with respect to solvent-treated control cultures (Fig. 8D), perhaps because under those non-proliferating and confluent conditions AhR+/+ MEFs normalize AhR expression regardless of the levels of senescence. In agreement with its senescence induction activity, Palbociclib significantly increased p16\textsuperscript{Ink4a} and p21\textsuperscript{Cip1} expression in MEFs of both genotypes, despite a less accused effect in AhR-/- MEFs likely due to their higher basal level of both proteins (Fig. 8E,F). The expression of p53 was not altered by Palbociclib in either genotype (Fig. 8G).

The correlation between AhR expression and induction of senescence in adult tissues was also analyzed \textit{in vivo} using the \textit{p16\textsuperscript{Ink4a}-3MR} transgenic mice in which
Nacarino-Palma et al., 2021

Senescent cells can be induced by treatment with doxycycline and eliminated through apoptosis by the metabolism of ganciclovir driven by the $p16^{Ink4a}$ promoter (Demaria et al., 2014) (Fig. 9A). Senescence induction by doxycycline reduced AhR expression in $p16^{Ink4a}$-3MR mice lungs (taken as target tissue) whereas co-treatment with ganciclovir restored receptor levels (Fig. 9B). Accordingly, levels of $p16^{Ink4a}$ and $p21^{Cip1}$ were upregulated by doxycycline to be reduced after the elimination of senescent cells by ganciclovir (Fig. 9C,D). In addition, the expression of $p53$ and the SASP factor $Mmp3$ was also modulated following induction or elimination of senescent cells (Fig. 9E,F).
**DISCUSSION**

Aging is one major life-threatening condition that increases the incidence of elderly-related diseases including cardiovascular, oncogenic and neurodegenerative pathologies negatively affecting life expectancy. An increasing number of studies are reporting different functions of AhR in aging (Bravo-Ferrer et al., 2019; Brinkmann et al., 2019; Eckers et al., 2016; Kaiser et al., 2020), having a positive or negative role depending on specie, cell phenotype and receptor levels (Mulero-Navarro and Fernandez-Salgueiro, 2016; Puga et al., 2009; Roman et al., 2018; Safe, 2001). On the other hand, AhR has emerged as a regulatory factor in pluripotency and stemness in different cell types including undifferentiated human teratoma cells (Ko and Puga, 2017; Ko et al., 2013; Morales-Hernandez et al., 2016). Accordingly, this receptor is required to block hepatocarcinogenesis induced by the toxic compound diethyl nitrosamine (Fan et al., 2010; Moreno-Marin et al., 2017), and its increased tumor burden in AhR-lacking mice involves the expansion of undifferentiated hepatic pluripotent cells (Moreno-Marin et al., 2017) that unusually remain in the adult liver even after age-dependent maturation (Moreno-Marin et al., 2018). Notably, aging induced a significant increase in spontaneous (e.g., not induced) liver tumors in AhR deficient mice that was accompanied by larger numbers of liver progenitor cells eventually contributing to tumorigenesis as they do to improve hepatic regeneration (Mitchell et al., 2006; Moreno-Marin et al., 2017). Since AhR expression and activation largely decrease with age in wild type mice, we suggest that: first, such partial deficiency in receptor levels may facilitate or account for the existence of a basal tumor load and a reduction in undifferentiated cells in those mice and, second, the remaining AhR expression could be still enough to restrain liver tumorigenesis decreasing its incidence as compared to fully depleted AhR/- animals.
Cell senescence has been linked to physiological aging and to age-related diseases (Campisi and Robert, 2014; Chiche et al., 2020). Remarkably, senescence not only increases during \textit{in vivo} reprogramming of tumors by OKSM pluripotency factors (Abad et al., 2013) but it also induces reprogramming \textit{in vivo} through p16^{Ink4a} (Mosteiro et al., 2016; Mosteiro et al., 2018). Thus, evidences support a functional interaction between senescence and stemness that impacts tumor development and tissue regeneration (Campisi and d'Adda di Fagagna, 2007; Chiche et al., 2017; Hernandez-Segura et al., 2018). In agreement with that hypothesis, aging in AhR deficient mice results in higher levels of liver senescence with up-regulation of inducers p16^{Ink4a}, p21^{Cip1}, IL1 and TNF\alpha. Moreover, AhR depletion also increased hepatic levels of SASP stimulating factors MCP-2 and MMP-12 and reduced those of SASP inhibitors FGF and HGF and VEGF. Since the secretory phenotype from senescent cells contributes to tumor development (Schosserer et al., 2017; Zeng et al., 2018) producing proinflammatory cytokines, growth factors, and extracellular matrix remodelers that facilitate the expansion of transformed cells, we suggest that the profile of SASP markers in \(AhR^{-/-}\) liver could contribute to their enhanced hepatocarcinogenesis. Pluripotency and reprogramming inducers OCT4 and NANOG, both repressed in an AhR-dependent manner during liver tumorigenesis and regeneration (Moreno-Marin et al., 2017), were over-expressed in AhR-null livers in parallel to their enhanced senescence and tumor burden. We therefore propose that AhR is at the crossroad of signalling pathways that integrate stemness, senescence and tumor development during liver aging. ChIP data indicate that AhR transcriptionally regulates the expression of p16^{Ink4a}, p21^{Cip1} and TNF\alpha, thus supporting a plausible causal role of this receptor in senescence.

AhR expression modulates senescence in different cell types and organs including mesenchymal embryonic fibroblasts (Alexander et al., 1998). Using passaging as a model...
for in vitro aging, we have found that MEFs from AhR-/- mice are more susceptible to develop senescence as determined by their higher levels of SA-β-Gal, p16<sup>ink4a</sup> and p21<sup>Cip1</sup>. These data again suggest that AhR inhibits senescence and, in fact, its increased expression in AhR+/+ MEFs with passaging may reveal a cellular response to control such process. Indeed, the Bcl-2 family inhibitor Navitoclax (Zhu et al., 2016) exerts a senolytic effect eliminating senescent cells more efficiently in absence of AhR, with downregulation of SA-β-Gal, p16<sup>ink4a</sup> and p21<sup>Cip1</sup>. AhR levels were reduced in AhR+/+ MEFs, in agreement with the idea that reduced senescence correlates with receptor inhibition. Consistently, CDK4/6 inhibitor Palbociclib/PD0332991 (Yoshida et al., 2016) produced an opposed response with respect to Navitoclax expanding senescence and, in parallel, increasing AhR levels early during the in vitro aging process. Interestingly, the effects of AhR on embryonic senescence were also seen in adult aged fibroblasts from AhR-/- mouse tail, in which cell cycle blockade and higher levels of SA-β-Gal, p16<sup>ink4a</sup> and p21<sup>Cip1</sup> correlated with senescence intensity. Further, aged AhR-/- adult fibroblasts had decreased mitochondrial activity that could result from their enhanced senescence and a more pronounced aged phenotype as previously suggested (Moro, 2019; Picca et al., 2019). Finally, elimination of senescent cells in vivo by activation of p16<sup>ink4a</sup> in p16<sup>ink4a</sup>-3MR transgenic mice further support our conclusion that lower senescence rates are associated to elevated AhR expression levels.

In summary, we provide here experimental evidence that the aryl hydrocarbon receptor is a molecular intermediate in the signalling pathways that govern the interaction between senescence and reprogramming. AhR would serve as a limiting factor in the control of both senescence and pluripotency eventually restricting tumor development with aging. Physiological modulation of AhR activity may represent a potential approach to circumvent progression of liver tumors in humans.
METHODS

Mice and treatments

AhR+/+ and AhR−/− mice (C57BL/6N x 129 sV) were produced by homologous recombination in embryonic stem cells as described previously (Fernandez-Salguero et al., 1995) and used at 4-6 weeks (young group) or 15-22 months (aged group). For AhR induction, mice were injected with 4 µg/kg 6-formylindolo[3,2-b]carbazole (FICZ) diluted in PBS. Untreated control mice were injected with the same volume of DMSO. At the end of treatments, mice were sacrificed, and their livers extracted.

p16Ink4a-3MR transgenic mice were generated as reported (Demaria et al., 2014). Mice at 4-7 months of age were treated i.p. with a single dose of 10 mg/kg doxycycline and seven days later with 25 mg/kg ganciclovir once per day for 5 consecutive days to clear senescent cells. Control mice received the same volume of vehicle (PBS). Experiments using mice were performed in accordance with the National and European legislation (Spanish Royal Decree RD53/2013 and EU Directive 86/609/CEE as modified by 2003/65/CE, respectively) for the protection of animals used for research. Experiments using mice were approved by the Bioethics Committee for Animal Experimentation of the University of Extremadura (Registry 109/2014) and by the Junta de Extremadura (EXP-20160506-1). Mice had free access to water and rodent chow.

Mouse embryonic fibroblasts (MEFs)

AhR+/+ and AhR−/− MEF cells were isolated from 14.5 d.p.c. mouse embryos as previously reported (Santiago-Josefat et al., 2001) and chemically induced senescence was performed as indicated (Guan et al., 2017). Briefly, MEFs cryopreserved for two days after isolation were thawed and grown in culture for 48 h in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin at 37°C and 5% CO₂ atmosphere. Cells were then
trypsinized and plated at a density of $4 \times 10^5$ cells per 10-cm culture dish. For senescence induction, cultures were treated with 4 μM of the CDK4/6 inhibitor Palbociclib/PD-0332991 (Merck, PZ-0199) for 8 days, refreshing media and drug on day 4. Treated cells were trypsinized, washed with PBS and plated in complete DMEM medium for at least 24 h before starting the experiments. For depletion of senescent cells, MEFs were treated for 48 h with 10 μM of the Bcl-2 inhibitor Navitoclax (MedChemExpress, HY-10087) as described (Zhu et al., 2016). In both treatments, equivalent volumes of solvent were used as vehicle controls.

**Adult primary fibroblasts**

Adult primary fibroblasts were obtained from tail tips of $AhR^+/+$ and $AhR^{-/-}$ mice. Mice were sacrificed and biopsies of the last 3 cm of tail were excised, cleaned in PBS and disinfected in 70% ethanol. After drying, tissues were sectioned in small pieces and placed in 0.25% trypsin solution (Invitrogen) in PBS and disaggregated by shaking during 90 min at 200 rpm and 37°C. The resulting digestion was filtered through a 40 μm mesh washing the remains of the digestion with RPMI medium. The filtrate was centrifuged at 200 g for 5 min and the resulting cell pellet was homogenized in RPMI medium containing 10% FBS, 50 μM 2-mercaptoethanol, non-essential amino acids (Gibco) and 1% penicillin/streptomycin at 37°C in a 5% CO$_2$ atmosphere. At that time, fibroblast cultures were considered to be at passage 0. After 24 h, cultures were washed with PBS and fresh medium added. Thereafter, the medium was changed every other day.

**Gene expression analysis**

Total RNA was isolated from $AhR^+/+$ and $AhR^{-/-}$ mouse livers using the Trizol reagent (Life Technologies). Following centrifugation, supernatants were precipitated with isopropanol, centrifuged again and pellets dissolved in DEPC-treated water. High Pure RNA Isolation Kit (Roche) was used to further purified RNA solutions from tissues and
from AhR+/+ and AhR−/− MEFs. To analyze mRNA expression by RT-qPCR, reverse transcription was performed using random priming and the iScript Reverse Transcription Super Mix (Bio-Rad). Real-time PCR was used to quantify the mRNA expression of AhR, p16Ink4a, p21Cip1, IL1, TNFα, Tpr53, Mmp3, Cyp1a1 and Gapdh using SYBR® Select Master Mix (Life Technologies) in a Step One Thermal Cycler (Applied Biosystems) essentially as indicated (Rico-Leo et al., 2016). Gadph was used to normalize gene expression (ΔCt) and 2−ΔΔCt to calculate changes in RNA levels with respect to control conditions. Primer sequences used are indicated in Supplementary Table 1.

**Immunoblotting.**

SDS–PAGE and immunoblotting were performed using total protein extracts obtained from AhR+/+ and AhR−/− mouse livers as previously described (Rico-Leo et al., 2016). Briefly, tissues were extracted and homogenized in ice-cold lysis buffer; following centrifugation, protein concentration was determined in the supernatants using the Coomassie Plus protein assay reagent (Pierce) and bovine serum albumin (BSA) as standard. Aliquots of 20-30 µg total protein were electrophoresed in 8% SDS-PAGE gels which were transferred to nitrocellulose membranes. After blocking in a TBS-T (50 mM Tris-HCl pH 7.5, 10 mM NaCl, 0.5% Tween 20) containing 5% non-fat milk, blots were sequentially incubated with the primary antibodies anti-AhR (Enzo 1:1000), anti-p53 (Cell signaling 1:1000) and anti-β-Actin (Sigma 1:1000) and secondary antibodies, washed in TBS-T and revealed using the Super-signal luminol substrate (Pierce). Blots were scanned and protein expression quantified in a ChemiDoc XRS+ equipment (Bio-Rad).

**Senescence-associated β-galactosidase activity**

Senescence-associated β-galactosidase activity (SA-β-gal) was analyzed in primary fibroblasts, isolated liver cells and liver tissue following published protocols (Debacq-
Chainiaux et al., 2009; Itahana et al., 2007). For primary adult fibroblasts and MEFs, the β-galactosidase fluorescent substrate C12FDG was added to the cultures at 60 µM concentration for 20 min and 37°C with gently shaking. C12FDG positive cells were quantified by flow cytometry using a Cytoflex S cytometer (Beckman Coulter) when analyzed in suspension, or with an Olympus FV1000 confocal microscope and the FV10 software (Olympus) when analyzed in attached cultures. In some experiments, MEFs were also stained with X-Gal as substrate to visualize the level of senescence by bright-field microscopy in a Olympus BX51 microscope. Isolated liver cells were obtained by mechanical disaggregation of liver tissue in a gentleMACS Octo Dissociator (Miltenyi). The resulting cell suspension was filtered through a 30 µm mesh and centrifuged for 5 min at 1800 g. Cell pellets were resuspended in PBS and incubated with the C12FDG substrate as indicated above. Cells were then resuspended in 0.1% BSA containing 10 µg/µl Hoechst 33258 and analyzed for senescence in a Cytoflex S cytometer (Beckman Coulter). For liver tissue, once fixed in buffered formaldehyde and included in paraffin, 3-5 µm liver sections were deparaffinized, rehydrated and stained for SA-β-Gal activity using X-Gal as substrate as described (de Mera-Rodriguez et al., 2019). Sections were observed and photographed using an Olympus BX51 microscope.

**Hematoxylin/eosin staining of liver sections**

Mouse livers were processed for H&E staining as described (Moreno-Marín et al., 2018). Tissues were fixed overnight at room temperature in buffered formalin and included in paraffin. Sections of 3 µm were deparaffinated, rehydrated and incubated for 3 min with hematoxylin; after washing with tap water, they were stained with eosin for 1 min. Sections were then dehydrated, mounted and observed in a NIKON TE2000U microscope using 4x (0.10 numeric aperture), 10x (0.25 numeric aperture) and 20x (0.40 numeric aperture) objectives.
**Immunofluorescence**

Liver sections were manually deparaffinated and rehydrated in PBS. Antigen unmasking was performed in citrate buffer at pH 6. After washing in PBS containing 0.05% Triton X-100 (PBS-T), non-specific epitopes were blocked by incubation for 1 h at room temperature in PBS-T containing 0.2% gelatin and 3% BSA (PBS-T-G-B). Sections were incubated overnight at 4°C with the following primary antibodies diluted in PBS-T-G-B: anti-p16\textsuperscript{Ink4a} (Santa Cruz Biotechnology 1:100), anti-p21\textsuperscript{Cip1} (Abcam, 1:100), anti-α-SMA (Sigma 1:200) anti-OCT4 (Santa Cruz Biotechnology 1:200) and anti-NANOG (Novus Biologicals 1:100). Following washing in PBS-T, sections were incubated for 1 h at room temperature with Alexa-488, Alexa-550 or Alexa-633 labeled secondary antibodies diluted in PBS-T-G-B. After additional washing, sections were dehydrated and mounted in PBS:glicerol (1:1).

Primary fibroblasts were grown in glass coverslips, washed with PBS and fixed for 10-15 min at room temperature with 3.5% paraformaldehyde in PBS. After washing, cells were permeabilized by incubation in PBS containing 0.1% Triton X-100 and 0.2% BSA, washed again in PBS and blocked for 30 min in 2% BSA in PBS. Specific primary antibodies anti-p16\textsuperscript{Ink4a} (Novus Biologicals 1:200), anti-p21\textsuperscript{Cip1} (Santa Cruz Biotechnology 1:100) and anti-Cyclin E (Santa Cruz Biotechnology 1:75) were added in blocking solution overnight at 4°C. Following three washes with PBS, secondary antibodies labeled with Alexa-488 or Alexa-633 were added for 1 h. Liver and fibroblast samples were visualized using an Olympus FV1000 confocal microscope (Olympus). Fluorescence analysis was done using the FV10 software (Olympus). DAPI was used to stain cell nuclei.

**Mitochondrial membrane potential**

Tail tip fibroblasts were seeded in 96-well plates and the mitochondrial membrane potential (MMP) was determined using the mitochondrial membrane potential kit (Sigma)
following the recommendations made by the manufacturer. The red/green fluorescence intensity ratio was used to determine MMP values. To determine mitochondrial activity, fibroblasts were stained with 4 nM tetramethylrodamine for 30 min in complete RPMI medium without phenol red at 37°C and 5% CO₂. Samples were analyzed using an Olympus FV1000 confocal microscope and the FV10 software (Olympus). Additional determination of MMP was done using the JC-10 dye. Fibroblasts were processed as indicated above and incubated with JC-10 for 30 min at 37°C and 5% CO₂. Samples were analyzed using a Cytoflex S flow cytometer (Beckman Coulter).

**Chromatin Immunoprecipitation (ChIP)**

Samples of liver tissue (60 mg) were finally minced, and DNA-protein interactions stabilized by incubation in 1% formaldehyde for 15 min at room temperature with agitation. Incubation was stopped by adding 0.125 glycine for 5 min. After washing in ice-cold PBS, samples were homogenized, and cell suspensions incubated for 10 min at 4°C in SDS lysis buffer containing protease inhibitors (Complete protease inhibitor cocktail, Roche). The remaining procedures were performed as described in previous reports (Carvajal-Gonzalez et al., 2009; Roman et al., 2008). Positive controls were done using input DNAs and negative controls were performed in absence of antibodies. Real-time PCR (qPCR) was carried out using IQ-SYBR Green in a Step One Thermal Cycler (Applied Biosystems). Specific primers used are indicated in Supplementary Table 2. Data are presented as percentage of DNA input in the antibody-containing immunoprecipitants minus the percentage of DNA input in the corresponding negative controls.

**Senescence associated secretory phenotype (SASP)**

Liver tissue was homogenized in commercial lysis buffer (Bio-Rad) supplemented with protease inhibitors (Complete protease inhibitor cocktail, Roche) using a ratio of 1 mg
tissue per 4 µl buffer. Samples were centrifuged at 500 g for 15 min and protein concentration determined in the supernatants. They were diluted with Bioplex sample diluent to a final concentration of 300 µg/ml. Blood plasma was obtained from whole blood taken from the left ventricle of the heart by cardiac puncture. Aliquots of 400-500 µl of blood were aspirated into a 2 ml syringe containing anticoagulant and immediately placed in EDTA containing tubes. Blood cells were separated by centrifugation at 1500 g for 15 min and the resulting plasma diluted 1:4 in Bioplex sample diluent. Cytokine content was analyzed using the Bio-Plex Multiplex immunoassay kit following the manufacturer's instructions.

**Hexokinase activity assay**

To determine glucose uptake by the liver, the Picoprobe Hexokinase activity kit (Biovision) was used following the manufacturer's instructions. Samples of 30 mg of liver tissue were homogenized in 300 µl of cold HK assay buffer. After centrifugation for 5 min at 10,000 g and 4°C, supernatants were collected and used following the instructions provided by the manufacturer.

**Quantification of liver progenitor cells**

Livers were removed from mice and processed using the gentleMACS Octo Dissociator kit (Miltenyi) to obtain homogeneous cell suspensions. Cell pellets were resuspended in 0.1% BSA in PBS and specific antibodies for undifferentiated liver cell markers CD133-PE (0.01 µg/µl) and CD326-EpCAM (0.3 µg/sample). A negative control without antibodies was used in each experimental condition. Cell suspensions were stirred for 20 min at 37°C and analyzed using a Cytoflex S Cytometer (Beckman Coulter).

**Statistical analyses**

Quantitative data are shown as mean ± SD. Comparisons between experimental conditions was done using GraphPad Prism 6.0 software (GraphPad). The student’s t test
was used to analyze differences between two experimental groups and ANOVA for the analyses of three or more groups. The Mann-Whitney non-parametric statistical method was used to compare rank variations between independent groups (*$P<0.05$; **$P<0.01$, ***$P<0.001$), ****$P<0.0001$).
ACKNOWLEDGMENTS

We are very grateful to Dr. Javier de Francisco Morcillo (Departamento de Anatomía, Biología Celular y Zoología, Universidad de Extremadura) for his assistance in the analysis of SA-β-Gal expression. The authors acknowledge the support of the Servicio de Técnicas Aplicadas a las Biociencias (STAB-SAIUEX) de la Universidad de Extremadura.

FUNDING

This work was supported by grants to P.M.F-S. from the Spanish Ministry of Economy and Competitiveness (SAF2017-82597-R, PID2020-114846RB-I00) and from the Junta de Extremadura (GR18006 and IB160210). E.M.R-L. was supported by the RTICC and the Junta de Extremadura. All Spanish funding is co-sponsored by the European Union FEDER program.

CONFLICT OF INTERESTS

The authors declare no conflict of interests.
REFERENCES


Nacarino-Palma et al., 2021


FIGURE LEGENDS

Figure 1. AhR depletion increases liver tumorigenesis with aging. (A) Representative tumors developed by AhR+/+ and AhR-/- at the indicated ages. (B) Haematoxylin and Eosin staining of liver tumor sections from AhR+/+ and AhR-/- mice at 22 months of age. Note the abundance of pycnotic nuclei in AhR-/- tumors. (C) Quantification of the number of liver tumors in mice of both genotypes at two different age intervals. (D) AhR mRNA expression in AhR+/+ livers at the indicated ages using RT-qPCR and the oligonucleotides indicated in Supplementary Table 1. (E) AhR protein levels were analyzed in liver extracts at the indicated ages by immunoblotting. β-Actin was used to normalize protein levels. (F) AhR+/+ mice were injected i.p. with 4 mg/kg FICZ and the mRNA levels of the AhR canonical target gene Cyp1a1 were determined by RT-qPCR using the oligonucleotides indicated in Supplementary Table 1. (G) Liver progenitor cells were analyzed by FACS using specific antibodies against CD133-PE and EPCAM-APC. Distribution of cell subpopulations and gating from representative experiments are shown. (H) Bone marrow progenitor cells were analyzed by FACS using the specific markers CD44-FITC and Sc1a-APC. Distribution of cell subpopulations and gating from representative experiments are shown. Gapdh was used to normalize target gene expression (ΔCt) and 2^-ΔΔCt to calculate changes in mRNA levels with respect to wild type or untreated conditions. Data are shown as mean ± SD (*P < 0.05; **P<0.01).

Figure 2. Cell senescence increases with age in AhR-deficient liver. (A) SA-β-Gal activity was analyzed in AhR+/+ and AhR-/- liver sections by staining with the chromogenic substrate X-Gal. (B) SA-β-Gal activity was analyzed by FACS in isolated liver cells (gentleMACS) using the fluorescent substrate C12FDG. (C-F) mRNA expression levels of senescence driver genes p16^ink4a (C) and p21^Cip1 (D) and SASP-related genes IL1 (E) and TNFα (F) were analyzed by RT-qPCR in AhR +/+ and AhR-/-
livers at the indicated ages. Oligonucleotides used are indicated in Supplementary Table 1. Gapdh was used to normalize target gene expression (ΔCt) and $2^{-\Delta\Delta\text{Ct}}$ to calculate changes in mRNA levels with respect to wild type or untreated conditions. Data are shown as mean + SD (*$P<0.05$; **$P<0.01$; ***$P<0.001$).

**Figure 3.** AhR/- livers overexpress senescence and undifferentiation/stemness markers. Protein levels for senescence markers p16$^\text{Ink4a}$ and p21$^\text{Cip1}$ and for pluripotency/stemness inducers NANOG and OCT4 were analyzed by immunofluorescence in liver sections of aged AhR+/+ and AhR/-/- mice and in hepatocarcinomas from AhR/-/- mice using specific antibodies. The expression of α-SMA was also analyzed as indicator of vasculogenesis. Conjugated secondary antibodies labelled with Alexa 488, Alexa 550 and Alexa 633 were used for detection. DAPI staining was used to label cell nuclei. An Olympus FV1000 confocal microscope and the FV10 software (Olympus) were used for the analysis. Scale bar corresponds to 50 μm.

**Figure 4.** AhR modulates the senescence-associated secretory phenotype with aging. (A). Chromatin immunoprecipitation (ChIP) for AhR binding to XRE binding sites located in the promoter of p16$^\text{Ink4a}$ (A), p21$^\text{Cip1}$ (B) and TNFα (C). qPCR was used to quantify changes in DNA binding and the results were normalized to the corresponding inputs. Amounts of MCP-2 (D), MMP12 (E), FGF (F) and HGF (G) were analyzed in liver homogenates from AhR+/+ and AhR/-/- mice at the indicated ages. Levels of HGF (H) and VEGF (I) VEGF were also determined in serum from mice of the same genotypes and ages. Bio-Plex Multiplex immunoassays kit were used. Oligonucleotides for qPCR are indicated in Supplementary Table 1. Gapdh was used to normalize target gene expression (ΔCt) and $2^{-\Delta\Delta\text{Ct}}$ to calculate changes in mRNA levels with respect to wild type or untreated conditions. Data are shown as mean + SD (*$P<0.05$; **$P<0.01$; ***$P<0.001$).
Figure 5. Senescence increases with aging in adult AhR-null fibroblasts. (A) AhR+/+ and AhR-/− TTFs were stained with the SA-β-Gal fluorescent substrate C12FDG to determine senescence levels by confocal microscopy. (B) SA-β-Gal activity was also measured by flow cytometry analyzing the percentage of C12FDG positive cells. (C-E) p16^{INK4a} (C), p21^{CIP1} (D) and Cyclin E (E) were analyzed by fluorescent confocal microscopy using specific antibodies in young and aged fibroblast cells. Conjugated secondary antibodies used were Alexa 488 and Alexa 633. DAPI staining was used to label cell nuclei. An Olympus FV1000 confocal microscope with FV10 software (Olympus) were used. (F) Percentage of TTFs in each cell cycle phase. Cell cycle analysis was performed by FACS using propidium iodide staining. (G) Mitochondrial membrane potential (MMP) was quantified by the percentage of TMRM positive cells analyzed by Cytoflex S cytometer (Beckman Coulter). (H) MMP was also calculated using the JC10 kit for mitochondrial membrane polarization (Sigma-Aldrich). The red/green fluorescence intensity ratio was used to determine MMP activity. Data are shown as mean + SD (*P <0.05; ** P <0.01).

Figure 6. Lack of AhR enhances in vitro cellular senescence in mouse embryonic fibroblasts. (A) Senescence profile of AhR+/+ and AhR-/− MEFs at the indicated passages as determined by the level of SA-β-gal activity analyzed by FACS using the β-galactosidase fluorescent substrate C12FDG. Results are normalized to wildtype MEFs at passage 2. (B) Representative flow cytometric profiles of senescent cells stained with C12FDG in AhR+/+ and AhR-/− MEFs at passage 5. (C) SA-β-Gal activity in AhR+/+ and AhR-/− MEFs at passage 5 as determined by cellular staining using X-Gal as substrate. (D) AhR mRNA expression was determined by RT-qPCR at the indicated cell culture passages. (E-G) mRNA expression of senescence driver genes p16^{INK4a} (E), p21^{CIP1} (F) and Trp53 (G) were determined in AhR+/+ and AhR-/− MEFs by RT-qPCR using the
oligonucleotides indicated in Supplementary Table 1. *Gapdh* was used to normalize target gene expression (ΔCt) and $2^{-\Delta \Delta Ct}$ to calculate changes in mRNA levels with respect to wild type or untreated conditions. Data are shown as mean + SD (**P<0.01; ***P<0.001).

**Figure 7.** Senolytic agent Navitoclax restores wild-type mRNA levels of senescence driver genes in AhR-/− MEFs. Embryonic fibroblast cultures at P4 or P5 were treated with vehicle or 10 μM Navitoclax for 48 h. (A) Bright-field microscopy of AhR+/+ and AhR-/− MEFs untreated or treated with Navitoclax. (B) Cell senescence measured as percentage of SA-β-Gal activity in MEF cells of both genotypes. SA-β-Gal activity was analyzed by FACS using the β-galactosidase fluorescent substrate C12FDG. Results are normalized to vehicle-treated wild-type MEFs. (C) X-Gal staining in untreated and Navitoclax-treated AhR+/+ and AhR-/− MEFs. (D) AhR mRNA expression was determined by RT-qPCR in both experimental conditions using the oligonucleotides indicated in Supplementary Table 1. (E) mRNA expression of senescence driver genes was determined in AhR+/+ and AhR-/− MEFs by RT-qPCR using the oligonucleotides indicated in Supplementary Table 1. *Gapdh* was used to normalize target gene expression (ΔCt) and $2^{-\Delta \Delta Ct}$ to calculate changes in mRNA levels with respect to wild type or untreated conditions. Data are shown as mean + SD (*P<0.05; **P<0.01; ***P<0.001).

**Figure 8.** CDK4/6 inhibitor Palbociclib induces senescence in MEF cells and mimicks AhR deficiency. Embryonic fibroblasts were grown in culture for 48 h and then plated at a density of 4 x10^5 cells per 10-cm plate. Two days later, cells were treated with 4 μM of CDK4/6 inhibitor Palbociclib/PD-0332991 for 8 days. (A) Bright-field microscopy of AhR+/+ and AhR-/− MEFs untreated or treated with Palbociclib. (B) Cell senescence measured as SA-β-Gal activity in AhR+/+ and AhR-/− MEFs. SA-β-Gal activity was analyzed by FACS using the β-galactosidase fluorescent substrate C12FDG.
Results are normalized to vehicle-treated wild-type MEFs. (C) X-gal staining in untreated and Palbociclib treated AhR+/+ and AhR-/ MEFS. (D) AhR mRNA expression was determined by RT-qPCR in AhR+/+ MEFs under both experimental conditions using the oligonucleotides indicated in Supplementary Table 1. Determinations were done after 8 days of treatment with Palbociclib or with vehicle control. (E) mRNA expression of senescence driver genes was determined in AhR+/+ and AhR-/ MEFs by RT-qPCR using the oligonucleotides indicated in Supplementary Table 1. Gapdh was used to normalize target gene expression (ΔCt) and 2−ΔΔCt to calculate changes in mRNA levels with respect to wild type or untreated conditions. Data are shown as mean + SD (*P<0.05; **P<0.01; ***P<0.001).

**Figure 9. AhR expression varies with the eradication of senescence in vivo in p16Ink4a-3MR transgenic mice.** (A) Schematic representation of the construct used to generate the p16Ink4a-3MR transgenic mice to deplete senescent cells in vivo by ganciclovir treatment. p16Ink4a-3MR mice at 4-7 months of age were treated with doxycycline (DOXO), doxycycline + ganciclovir (DOXO+GCV) or vehicle PBS (vehicle). mRNA expression of AhR (B), p16Ink4a (C), p21Cip1 (D), p53 (E) and Mmp3 (F) was determined by RT-qPCR in lung tissue using the oligonucleotides indicated in Supplementary Table 1. Gapdh was used to normalize target gene expression (ΔCt) and 2−ΔΔCt to calculate changes in mRNA levels with respect to wild type or untreated conditions. Data are shown as mean + SD (*P<0.05; **P<0.01).

**SUPPLEMENTARY MATERIAL**

**Supplementary Figure 1.** (A) mRNA expression of the glucose transporter Glut4 was determined by RT-qPCR in AhR+/+ and AhR-/ livers at the indicated ages using the oligonucleotides indicated in Supplementary Table 1. Gapdh was used to normalize target
gene expression ($\Delta Ct$) and $2^{-\Delta\Delta Ct}$ to calculate changes in mRNA levels with respect to wild type or untreated conditions. (B) Glucose uptake was measured in young and aged $AhR^+/+$ and $AhR^-/-$ livers by the Picoprobe Hexokinase activity assay kit (Biovision). Data are shown as mean ± SD. (*$P<0.05$; **$P<0.01$).

**Supplementary Table 1:** Oligonucleotide sequences used for mRNA expression analysis

**Supplementary Table 2:** Oligonucleotide sequences used for Chromatin immunoprecipitation (ChIP)
**Figure 1**

(A) Liver tissue of mice with various genotypes and ages:
- Liver 16M (AhR+/+)
- Liver 18M (AhR−/−)
- Liver 22M (AhR+/+)

(B) Tumoral tissue images:
- AhR+/+ (4x, 10x, 20x magnification)
- AhR−/− (4x, 10x, 20x magnification)

(C) Incidence of tumors:
- Comparison of AhR+/+ and AhR−/− mice over 12-15 months and 23-24 months.

(D) mRNA expression of AhR relative to Gapdh in different genotypes and ages:
- AhR+/+ young
- AhR+/+ 15M
- AhR+/+ 17M
- AhR+/+ 22M
- AhR−/− young
- AhR−/− 15M
- AhR−/− 17M
- AhR−/− 22M

(E) Western blot analysis of AhR and β-Actin:
- AhR+/+ young
- AhR−/− young
- AhR+/+ 15 month
- AhR+/+ 17 month
- AhR+/+ 22 month

(F) mRNA expression of Cyp1a1 relative to Gapdh:
- AhR+/+ young
- AhR+/+ young FICZ
- AhR+/+ old
- AhR+/+ old FICZ

(G) Flow cytometry analysis of liver progenitors:
- Liver AhR+/+
- Liver AhR−/−

(H) Flow cytometry analysis of bone marrow progenitors:
- Bone marrow AhR+/+
- Bone marrow AhR−/−
Figure 2

(A) Immunohistochemistry of AhR+/+ and AhR-/- mice, showing differences in expression between young and old mice.

(B) Bar graph showing relative senescence in AhR+/+ and AhR-/- mice, with young and old groups.

(C) mRNA expression of p16^Ink4a/Cdkn2a in AhR+/+ and AhR-/- mice, with young and old groups.

(D) mRNA expression of p21^Cdkn1a in AhR+/+ and AhR-/- mice, with young and old groups.

(E) mRNA expression of IL1 in AhR+/+ and AhR-/- mice, with young and old groups.

(F) mRNA expression of TNFα in AhR+/+ and AhR-/- mice, with young and old groups.
Figure 3

<table>
<thead>
<tr>
<th></th>
<th>AhR+/+</th>
<th>AhR/-</th>
<th>AhR/- tumor</th>
</tr>
</thead>
<tbody>
<tr>
<td>p16</td>
<td><img src="p16" alt="Image" /></td>
<td><img src="p16" alt="Image" /></td>
<td><img src="p16" alt="Image" /></td>
</tr>
<tr>
<td>p21</td>
<td><img src="p21" alt="Image" /></td>
<td><img src="p21" alt="Image" /></td>
<td><img src="p21" alt="Image" /></td>
</tr>
<tr>
<td>NANOG</td>
<td><img src="NANOG" alt="Image" /></td>
<td><img src="NANOG" alt="Image" /></td>
<td><img src="NANOG" alt="Image" /></td>
</tr>
<tr>
<td>α–SMA</td>
<td><img src="%CE%B1%E2%80%93SMA" alt="Image" /></td>
<td><img src="%CE%B1%E2%80%93SMA" alt="Image" /></td>
<td><img src="%CE%B1%E2%80%93SMA" alt="Image" /></td>
</tr>
<tr>
<td>OCT4</td>
<td><img src="OCT4" alt="Image" /></td>
<td><img src="OCT4" alt="Image" /></td>
<td><img src="OCT4" alt="Image" /></td>
</tr>
</tbody>
</table>
Figure 4

A. **p16^ink4**

DNA binding (% of input)

- Young
- 15 months
- 22 months

B. **p21^Cip1**

DNA binding (% of input)

- Young
- 15 months
- 22 months

C. **TNFα**

DNA binding (% of input)

- Young
- 15 months
- 22 months

D. **MCP-2**

pg/ml

- AhR+/+ 15 months
- AhR/- 15 months
- AhR+/+ 22 months
- AhR/- 22 months

E. **MMP-12**

pg/ml

- AhR+/+ 15 months
- AhR/- 15 months
- AhR+/+ 22 months
- AhR/- 22 months

F. **FGF**

pg/ml

- AhR+/+ 15 months
- AhR/- 15 months
- AhR+/+ 22 months
- AhR/- 22 months

G. **HGF**

pg/ml

- AhR+/+ 15 months
- AhR/- 15 months
- AhR+/+ 22 months
- AhR/- 22 months

H. **HGF** (serum)

pg/ml

- AhR+/+ 15 months
- AhR/- 15 months
- AhR+/+ 22 months
- AhR/- 22 months

I. **VEGF** (serum)

pg/ml

- AhR+/+ 15 months
- AhR/- 15 months
- AhR+/+ 22 months
- AhR/- 22 months
Figure 6

**A**
Relative cell senescence (β-Gal activity) for **AhR**+/+ and **AhR**−/− at different passages (P2, P3, P4, P5).

**B**
Flow cytometry analysis of C127FOG cells for **AhR**+/+ and **AhR**−/−, showing C127FOG− cells percentages: 54.95% for **AhR**+/+ and 71.11% for **AhR**−/−.

**C**
Confocal microscopy images for **AhR**+/+ and **AhR**−/− at 20x and 40x magnifications.

**D**
RNA expression analysis of **AhR** gene expression relative to **Gadph** at different passages (P2, P3, P4, P5).

**E**
RNA expression analysis of **p16**/Cdkn2a, **p21**/Cdkn1a, and **Trp53** genes relative to **Gadph** at different passages (P2, P3, P4, P5).
Figure 8

A) Vehicle vs Palbociclib

AhR+/+

AhR-/-

20X

B) Relative fluorescence intensity (C/2EG signal)

<table>
<thead>
<tr>
<th></th>
<th>Vehicle</th>
<th>Palbociclib</th>
<th>Vehicle</th>
<th>Palbociclib</th>
</tr>
</thead>
<tbody>
<tr>
<td>AhR+/+</td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
</tr>
<tr>
<td>AhR-/-</td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
</tr>
</tbody>
</table>

C) Vehicle vs Palbociclib

AhR+/+

AhR-/-

20X

D) mRNA expression relative to Gadd45a

<table>
<thead>
<tr>
<th></th>
<th>Vehicle</th>
<th>Palbociclib</th>
<th>Vehicle</th>
<th>Palbociclib</th>
</tr>
</thead>
<tbody>
<tr>
<td>AhR+</td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
</tr>
<tr>
<td>AhR-</td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
</tr>
</tbody>
</table>

E) mRNA expression relative to Gadd45a

<table>
<thead>
<tr>
<th></th>
<th>Vehicle</th>
<th>Palbociclib</th>
<th>Vehicle</th>
<th>Palbociclib</th>
</tr>
</thead>
<tbody>
<tr>
<td>p16</td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
</tr>
</tbody>
</table>

F) mRNA expression relative to Gadd45a

<table>
<thead>
<tr>
<th></th>
<th>Vehicle</th>
<th>Palbociclib</th>
<th>Vehicle</th>
<th>Palbociclib</th>
</tr>
</thead>
<tbody>
<tr>
<td>p21</td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
</tr>
</tbody>
</table>

G) mRNA expression relative to Gadd45a

<table>
<thead>
<tr>
<th></th>
<th>Vehicle</th>
<th>Palbociclib</th>
<th>Vehicle</th>
<th>Palbociclib</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tpr53</td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
</tr>
</tbody>
</table>
Figure 9

A

\[ \text{p16 promoter} \rightarrow \text{LUC} \rightarrow \text{mRFP} \rightarrow \text{HSV-TK} \]

HVS-TK

\[ \text{GCV} \rightarrow \text{P-GCV} \rightarrow \text{Cell death} \]

B

AhR

mRNA expression relative to Gapdh

C

\[ p_{16}^{\text{Lkn4/Cdkn2a}} \]

mRNA expression relative to Gapdh

D

\[ p_{21}^{\text{Cdkn1a}} \]

mRNA expression relative to Gapdh

E

Trp53

mRNA expression relative to Gapdh

F

mmp3

mRNA expression relative to Gapdh
Supplementary Figure 1

**Figure 1**

(A) *Glut4* mRNA expression relative to Gapdh.

(B) Glucose uptake.